Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Visvesh Jeyalan"'
Autor:
Mohamed Farag, Visvesh Jeyalan, Jose Luis Ferreiro, Young-Hoon Jeong, Tobias Geisler, Diana A. Gorog
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
Current guidelines for patients with acute coronary syndrome (ACS) recommend dual antiplatelet therapy (DAPT) for 12 months. Since bleeding is the main Achilles' heel of DAPT, in recent years several randomized controlled trials have evaluated the sa
Externí odkaz:
https://doaj.org/article/366e7e87a6254370a0df0680cf5997c7
Autor:
Visvesh Jeyalan, David Austin, Shu Xian Loh, Vincent Kharisma Wangsaputra, Ioakim Spyridopoulos
Publikováno v:
Cells, Vol 12, Iss 19, p 2377 (2023)
Dilated cardiomyopathy (DCM) is a cardiac condition with structural and functional impairment, where either the left ventricle or both ventricular chambers are enlarged, coinciding with reduced systolic pump function (reduced ejection fraction, rEF).
Externí odkaz:
https://doaj.org/article/2e550af2c4614bc0a07a6c64e01c8ef7
Autor:
Diana A. Gorog, Visvesh Jeyalan, Rafaella I. L. Markides, Eliano P. Navarese, Young-Hoon Jeong, Mohamed Farag
Publikováno v:
Thrombosis and Haemostasis.
Background Guideline-recommended dual antiplatelet therapy (DAPT; aspirin plus prasugrel/ticagrelor) for 12 months in acute coronary syndrome (ACS) patients increases bleeding, with East Asians (EAs) exhibiting higher bleeding and lower ischemic risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77f2fc21600ef567baedfc9ec823c9dd
https://doi.org/10.1055/s-0043-57030
https://doi.org/10.1055/s-0043-57030
Publikováno v:
Cardiovascular Revascularization Medicine. 36:164-165
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87c91a482d52128f9cf75bfbc9bb49d6
https://doi.org/10.1016/j.carrev.2021.05.002
https://doi.org/10.1016/j.carrev.2021.05.002